TCT-170 Conduction System Disorders After Transcatheter Tricuspid Valve Replacement
Recommended Citation
Rangavajla G, Abdelhai O, Nguyen F, Giustino G, Fang J, Dawdy J, Engel Gonzalez P, Villablanca P, Lee J, Parikh S, Zweig BM, O’Neill B. TCT-170 Conduction System Disorders After Transcatheter Tricuspid Valve Replacement. J Am Coll Cardiol 2024; 84(18):B419-B420.
Document Type
Conference Proceeding
Publication Date
10-29-2024
Publication Title
J Am Coll Cardiol
Abstract
Background: Transcatheter tricuspid valve replacement with the Evoque valve was recently approved by the U.S. Food and Drug Administration as a transcatheter therapy for severe tricuspid regurgitation, but initial data suggest a high rate of conduction system disorders (CSDs). As real-world data are limited, we aimed to characterize predictors of post-TTVR CSD and associations with clinical outcomes. Methods: Patients undergoing Evoque at Henry Ford Hospital February-May 2024 were included; those with aborted procedures, prior bundle branch blocks (BBB), or prior pacemakers (PPM) were excluded. Predictors of new CSD, defined as new BBB or complete heart block (CHB) were assessed, and we analyzed the association between CSD and a composite of death or heart failure hospitalization. Results: Of 28 total Evoque patients, 18 were excluded (aborted procedure: 6, prior BBB: 3, prior PPM: 12). Of the 10 studied patients, 5 developed new CSD: 4 with RBBB and 1 with CHB requiring new PPM. Percent oversizing of the valve relative to the native annulus was not associated with CSD; however, greater baseline LVEF was associated (Figure 1A, P <0.05). New CSD post-Evoque was not associated with death or heart failure hospitalization over a median 11-day (IQR 3-32) follow-up (Figure 1B). [Formula presented] Conclusion: Although sample size and follow-up time were limited, we report early real-world data of post-Evoque CSD. Baseline LVEF, but not percent oversizing, was associated with new CSD. We aim to conduct further studies to better inform patient selection by identifying reliable predictors and clinical outcomes of post-Evoque CSD. Categories: STRUCTURAL: Valvular Disease: Tricuspid.
Volume
84
Issue
18
First Page
B419
Last Page
B420
